We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Raymond L. Dirks Internet Research Tribunal Thread
An SI Board Since May 2002
Posts SubjectMarks Bans
544 25 0
Emcee:  StockDung Type:  Unmoderated

=Raymond L. Dirks =Gene G. Marcial =Sharon Di Stefano=Laurel Moody

Please note: There are not spiders in Sharons hair.

Ray dirks floating this much younger Ray Dirks picture in recent press release fo promote stock scam Message 30421393

Stock Crook Ray Dirks today


Where Fashion meets Finance, and where Stocks meet Blonds.


The "ShortBuster Club" was run by Ray Dirks. Dirks would try to organize short squeezes. Most of his

companies he tried to protect eventually succumbed to failure -- not because of short sellers but because of

fundamental failures of the business.

[More information on Ray Dirks:
  1. New York Times: Wall Street;A Fast-and-Loose 'Short Buster' 1992 written by Susan Antilla
  2. Businessweek: Tops With The Shortbusters 1998

Raymond Louis Dirks (CRD #601699, Registered

Representative, New York, New York)
submitted an Offer of

Settlement in which he was fined $25,000 and suspended from

association with any NASD member in any capacity for 30 days.

Without admitting or denying the allegations, Dirks consented to

the described sanctions and to the entry of findings that he

wrote research reports that contained “Strong Buy”

recommendations that did not define what was meant by a

“Strong Buy,” and did not disclose any risks that could impede

the achievement of targets or estimates. The findings also stated

that Dirks failed to disclose in a report that company auditors

had issued a going concern on the company before the issuance

of the report. NASD also found that in one report Dirks failed to

disclose that his member firm was a market maker in the

company’s securities at the time the report was published. In

addition, NASD found that reports omitted material facts and

included price target projections and revenue estimates that

were exaggerated, unwarranted, misleading, and without a

legitimate basis, and forecast events that were unwarranted in

light of the speculative nature of the company’s business.

Let’s talk about Ms. Di Stefano’s résumé for a minute. Until January, she worked for Meyers Associates in

New York. Granted, she was only there for three months, but this is a firm run by Bruce Meyers, a former broker

at the defunct and fraudulent D.H. Blair who went on to co-found Janssen/Meyers, which also got up to no good

in the penny stock realm. Ms. Di Stefano has worked for no less than 12 brokerage firms since the late 1980s,

including Ross Mandell’s Sky Capital, H.J. Meyers & Co. and Josephthal & Co.—all three infamous players in

the shady underworld of penny stock fraud. She’s like the Where’s Waldo of crappy brokerages.

Another supporter: Ray Dirks of, an “analyst” of such notoriety that there are Internet chat room

threads dedicated to reminding investors to steer clear of anything he recommends. And then there’s the fact

that parent company describes itself as the place where “fashion meets finance … the

intersection where tomorrow’s hottest stock ideas are being discovered by today’s top entertainment talents.”

Huh? We’re also told that the company’s CEO, Laurel Moody, has “a wherewithal unmatched in the industry”—

one she apparently honed as investor relations officer for … boiler room Sky Capital. Do all of these people

come from the same shady corporate family tree?

Up & Down the Street
Tough to Swallow: Paper Trail Behind ‘Breakthrough’ Leads to Penny-stock Profiteers For what, insulin?
By Duff McDonald | 02/26/14 11:03am

Nadav Kidron, the C.E.O. of Oramed, with an insulin pill. (Photo via Baz Ratner/Reuters)

Let me get one thing straight: I was predisposed to cheer for Oramed Pharmaceuticals, a tiny Jerusalem-based drug developer that has been working on an orally ingested insulin pill for more than a decade. That’s one of the holy grails of disease management, with a potential market of nearly $20 billion per year.

Oramed stock, which traded below $10 for most of 2013, took off like a rocket in December and flirted with $30 in January as both Oramed executives and a chorus of supporters whipped investors into a frenzy over some supposedly great clinical trial results they were due to release at the Tel Aviv Stock Exchange at the end of the month. The company even raised $16 million in December on the heels of that strong stock price movement.

Well, the results weren’t all that, and the stock has since given back most of that gain, to its current level of $16. Is this a buying opportunity? Oramed CEO Nadav Kidron is certainly bullish. He has taken any opportunity he can to tout his company’s prospects on the likes of Bloomberg TV and Fox Business. And Oramed’s current market capitalization of $150 million is minuscule compared to the opportunity, and in January, the company filed to raise as much as $100 million. Should you be buying? Short answer: No.

There are a few major challenges when it comes to oral insulin. The first is that digestive enzymes that break down proteins in the processing of food can also break down the amino acid-based proteins in insulin, rendering it useless to the diabetic. And even if it survives that process, the insulin then needs to pass through the wall of the intestine and make its way into the bloodstream, at which point there’s another challenge, which is that insulin proteins need to be absorbed in precise quantities and stay in the bloodstream for the right amount of time, or a diabetic runs the risk of, well, dying.

Novo Nordisk, the world’s largest producer of insulin, has been working on its own insulin pill for years, and in October, the Danish company announced plans to spend up to $3.65 billion through 2020 developing six diabetes pills it has under development. But with just two oral insulin pills in Phase I clinical trials, even Novo isn’t yet close enough to confidently say that it’s ever going to come up with an effective pill. And the road to oral insulin is marked with other casualties. Pfizer, for example, abandoned an inhaled insulin product in 2007. “I’m not going to hold my breath on this one,” Dr. Robert Ratner, the chief science and medical officer for the American Diabetes Association, told Reuters late last year.

So let’s get back to Oramed. It’s true that the company is ahead of the competition in clinical trials of its flagship product, ORMD 0801, which is based on research from Jerusalem’s Hadassah Medical Center. And the Phase IIa trial results in January did appear to show that the pill was safe—none of the 30 patients who participated in the one-week trial showed adverse reactions to its use. That’s important. What’s more important, though, is whether or not the damn thing works—whether this pill will help the sick man lookin’ for the doctor’s cure.

I asked Oramed CEO Nadav Kidron about the pill’s efficacy this week, and he pointed me to data in the company presentation that did show lowered glucose levels in those participating in the trial. But he also admitted that the data referred to just eight people. In other words, it wasn’t statistically significant. If you think eight is a small number, I have another one for you: 12. Look at the R&D that has gone into ORMD 0801; you might think you’re looking at a typo. The company has spent a total of just $12 million in cumulative R&D since 2002. Novo Nordisk spent $635 million on R&D in the fourth quarter of 2013 alone.

Let’s give Oramed the benefit of the doubt and assume that the money was very well spent. And why wouldn’t we? The chief scientific officer and director is 73-year-old Miriam Kidron, Ph.D. She’s a pharmacologist and biochemist. So far, so good. Dr. Ehud Arbit, M.D., the former chief neurosurgeon at New York’s Memorial Sloan-Kettering Cancer Center, is the company’s director of R&D. Also impressive, yes? Maybe not. Dr. Arbit was twice accused of operating on the wrong side of patients’ brains, and he was dismissed from his Sloan-Kettering post in 1995. The company does have some luminaries on its scientific advisory board, including the former head of diabetes research at Merck. But an advisory board isn’t a management team.

And the CEO Nadav Kidron? That’s Miriam’s 39-year-old son. Asked recently about his gig, Mr. Kidron said, “[My mother is] the chief scientist. I just went for the ride to do the business side.” (And in a company car, apparently: Recent filings show that Oramed spends upward of $10,000 per year on automobile-related expenses for each Kidron, as well as other executives—this for a company that has incurred aggregate losses of more than $20 million since inception with no actual revenues in sight.)

So what has this group come up with for that $12 million? Oramed says ORMD 0801 contains a protease inhibitor and other “technologies” that promise to solve the absorption problem. It even has a patent! A close reading of the patent leads one to this list of ingredients in the pill: 1) a gelatin or enteric coated capsule, 2) a chelating agent called EDTA, 3) omega-3 fatty acid, a.k.a. fish oil, 4) a protease inhibitor called Soybean Trypsin, a.k.a. soy powder, 5) a chemical called SNAD and 6) insulin.

So why don’t we make some ORMD-801 in our own kitchen? Here’s my best guess at what it would cost to do so. Gelatin capsules from the Vitamin Shoppe, $6.29; a bottle of EDTA, $7.49; some omega-3 fish oil, $15.99. And for the soy powder, Oramed says it has its own special formula, so we won’t skimp on ours—the fancy stuff costs $58. As for SNAD, that’s an oral drug delivery agent developed by Emisphere Technology, sold under the brand name Eligen. Clinical trials using Eligen for drug delivery programs for calcitonin, parathyroid hormone and growth hormone have all failed, and oral insulin and vitamin B12 are that company’s only horses left running, although the B12 stuff was recently taken off the market. Anyway, you used to be able to get it for $21 per bottle. Finally, the insulin: You can purchase 100iu of it from Walgreens for $92. Total cost of materials: $200.

Of course, if you’re going to make this magic pill, you will need some equipment. Start with a capsule machine for $15.69. Maybe even splurge on a “gorgeous” mortar and pestle, for $16.95, and a scale, for $10.53. Total equipment cost: $43.

The only component of ORMD-801 that requires a prescription is the insulin. As far as I can tell, everything else can be bought over the counter. And it’s hard to see what’s proprietary beyond its unique soy power formulation. It doesn’t seem to have invented a whole lot. Suddenly, the $12 million doesn’t seem like too little investment but too much. I spent less than $250 to make the same pill. Well-known biotech journalist Adam Feuerstein of blasted Oramed earlier this month, concluding that the hyped-up data—and thus the pill—was “completely worthless.” But that’s being a little harsh. Let’s call it $250, shall we?

The Emisphere connection is an interesting one. Both Drs. Arbit and Kidron used to work there. Emisphere also has a partnership with Novo Nordisk, which it entered into in 2008, and Novo re-upped in 2013 with a $10 million payment. If the SNAD stuff does work—and we don’t know that it does—Novo has already licensed it. It doesn’t need Oramed, which could be one reason it hasn’t already bought the upstart. Sure, the people at the company believe in themselves. The only problem is that no one else seems to, other than some cheerleaders of, shall we say, questionable objectivity.

Say, for example, Sharon Di Stefano, who has churned out a number of ridiculous posts about Oramed on stock chat site Seeking Alpha that the company links to on its own website as if the posts were “news.” Last June, Ms. Di Stefano wrote, “Oramed’s Unparalleled Insulin Technology Pipeline Comes at a Time When Acquirers Need It Most.” And then in July, “Oramed: An Early-Stage Biotech Company With Huge Potential.” And November: “Oramed’s Success in Type I Diabetes Could Solve Novo Nordisk’s Problems.” Stick with Oramed, she says, because Novo Nordisk could “make a play” for it. Really? When? Why? Dr. Kidron says the company is “in discussions” with potential partners and will partner “at the right time.” But it has had a decade to do so, and with Oramed spending pretty much zero on R&D, the pill surely hasn’t changed much during that time.

Let’s talk about Ms. Di Stefano’s résumé for a minute. Until January, she worked for Meyers Associates in New York. Granted, she was only there for three months, but this is a firm run by Bruce Meyers, a former broker at the defunct and fraudulent D.H. Blair who went on to co-found Janssen/Meyers, which also got up to no good in the penny stock realm. Ms. Di Stefano has worked for no less than 12 brokerage firms since the late 1980s, including Ross Mandell’s Sky Capital, H.J. Meyers & Co. and Josephthal & Co.—all three infamous players in the shady underworld of penny stock fraud. She’s like the Where’s Waldo of crappy brokerages.

Another supporter: Ray Dirks of, an “analyst” of such notoriety that there are Internet chat room threads dedicated to reminding investors to steer clear of anything he recommends. And then there’s the fact that parent company describes itself as the place where “fashion meets finance … the intersection where tomorrow’s hottest stock ideas are being discovered by today’s top entertainment talents.” Huh? We’re also told that the company’s CEO, Laurel Moody, has “a wherewithal unmatched in the industry”—one she apparently honed as investor relations officer for … boiler room Sky Capital. Do all of these people come from the same shady corporate family tree?

Mr. Dirks told investors to buy Oramed in July 2012 at $0.30 per share. They would have profited handsomely following that advice. Of the reasons he cited for buying it, however, included ORMD 0801’s “ease of use” (i.e., it’s a pill), “more efficient manufacturing once approved to fatten profits quicker” (it hasn’t been approved, nor is “more efficient manufacturing” guaranteed), “greater acceptance by physicians” (uh, what?), “less side effects meaning a decreased burden on our health care system” (buy Oramed, and you’re buying America) and “appeal to patients” (yes, if it works, but it hasn’t been shown to do so). It’s all empty bullshit, basically.

But let’s get back the question of whether or not it works. And the answer is that we just don’t know. Despite all the pretense of “news” every few months, Oramed has merely announced the results of successive Phase II safety trials over and over again— in August 2008, July 2009, May 2010, April 2013 and just last month—with the same results, namely that the pill is safe. That’s better than saying it’s unsafe, but it’s not the same as saying it works. In fact, the reason it might be safe could be that the digestive system has simply destroyed the contents of the pills, rendering them not just “safe” but also useless. It has applied with the FDA to run a Phase IIb trial to show efficacy next. All eyes will be on those results.

In an October interview with Bloomberg Television, Mr. Kidron suggested that $8 million in balance sheet cash wasn’t what it was—a decidedly paltry amount for a firm vying for one of biotech’s biggest prizes—and that, “as an Israeli company, though we are [listed on] Nasdaq, we are able to get a lot done on a much smaller and tight budget.” It has raised another $16 million since then, but that’s still not a lot of money in the world of drug development. And the cost of scientific discovery doesn’t recognize geographical boundaries. And if you ask me, it doesn’t really seem to have gotten “a lot done” at all. So its pill won’t kill you. Neither will not buying its stock.

For lack of verifiable and significant scientific progress, Oramed’s executives and cheerleaders have been content to remind us that an effective insulin pill would make a lot of money. Great. But we already knew that.

Follow us: @newyorkobserver on Twitter | newyorkobserver on Facebook

Follow us: @newyorkobserver on Twitter | newyorkobserver on Facebook


MARKET ALERT – Wall Street Rumblings – Issue #CLXXIII dated March 30, 2014 by Ray DirksPosted on admin on March 30, 2014 // Leave Your Comment

Market Alert – Wall Street Rumblings Up, Down, and Around Wall Street – March 30, 2014 -

Issue #CLXVIII – featuring RAYDIRKS Research – with Ray Dirks and his team of

Money Managers and Security Analysts – in association with the internationally followed

Web Sites and, where Fashion meets Finance, and where Stocks meet Blonds.

Last week was a tough time for the U.S. stock market, which fell about 0.5% on average,and the weakest areas were biotech and technology stocks, particularly small cap shares.

To quote from “The Trader” column in tomorrow’s Barron’s, the Dow Jones Business and
Financial Weekly, “It was a good week to be out of U.S. stocks as broad market indexes here gave up ground. That was in marked contrast to major markets around the world, which posted solid rises. After American stocks smoked foreign equities last year, this was a rare week of role reversal.

In sympathy with overseas equities , the largest U.S. companies – which tend to get a good chunk of their sales from international sources – did better. Small-company stocks, typically more domestically focused, fell sharply. Among them, technology and biotech did especially poorly.

World equities, not including the U.S., were up 1.8%; German stocks rose nearly 3%, Japan was up 1.5%.

On these shores, the Standard & Poor’s 500 index dropped nine points, or 0.5%, to 1,858. The Nasdaq Composite index lost 121 points, or 2.8%. to 4,156. The Russell 2000 small-company index dropped 42 points, or 3.5%, to 1,152. Only the Dow Jones Industrial Average gained, up 0.1%, 20 points, to 16,323.

With the first quarter about to end, the S&P 500 is essentially flat, a far cry from the 10% rise in the same year-ago period. The bond market continues to confound. Though many have expected interest rates to rise since the Fed announced the tapering in mid-December, bond prices are higher and rates lower. The lower end of the Treasury yield curve has flattened a little bit, suggesting bond investors don’t see much in the way of U.S. economic growth. Maybe that’s why some have put their money to work overseas.”

The sell-off provides investors and readers of this article an opportunity for the Rumblings readers with to buy many our Favorite Stocks for 2014 at very attractive prices currently. Ray Dirks and his team are listing below ten of these stocks – with very big upside potential, in our opinion – followed by some paragraphs from recent articles published in the press or on the Internet which discusses these companies in a way that provides reasons for visualizing higher prices for their stocks this year.

Company Name Stock Symbol March 28 Price Price Range – 12 Months

Fusion Telecommunications International FSNN $ 0.10 $ 0.18 - $ 0.06

Victory Electronic Cigarettes ECIG $13.48 $ 60.00 – $

Neuralstem CUR $ 3.88 $ 4.80 – $ 1.00

Cover-All Technologies COVR $ 1.43 $ 1.80 – $ 1.00

Oramed Pharmaceuticals ORMD $ 10.56 $ 32.00 -$ 5.00

ProMetic Life Sciences PFSCF $ 1.09 $ 1.49 $ 0.30

Arabian-American Development ARSD $ 10.42 $ 13.17 -$ 7.07

AFLAC AFL $ 62.66 $ 67.62 -$48.04

BioTime BTX $ 3.11 $ 4.82 – $3.01

Hartford Financial Services HIG $ 34.88 $ 36.76- 24.67

Fusion (FSNN) at $0.10 is the Number One choice of Wall Street Rumblings by Ray Dirks and his team of Money Managers and Security Analysts for Capital Appreciation in the Short Term (3-6 months) and the Long Term (6 months to 2 years). In summary, Rumblings thinks Fusion will sell at $1.00 within 3 to 6 months – by the 4th of July – and FSNN will sell at $3.00 per share within 6 months to 2 years – by January 15, 2015. !! This reflects the fact that Fusion – one of the leading companies in the cloud with revenues well over $100 million annually and EBITDA of approximately $15 million annually currently – is by far the fastest growing cloud company with the strongest position in the United States in the health care vertical space, which Ray Dirks and his team thinks will grow by 50 % to 75% per year in revenues and EBITDA for at least the next five years. This will be reflected soon in the FSNN stock price because Fusion will be listed on the national Nasdaq market before July 4th – after reverse-splitting its stock. Fusion’s outstanding management team is led by Chief Executive Officer Matthew Rosen, and the company has the best Board of Directors and Advisory Board that we know of in the Technology and the Cloud Spaces. Fusion recently completed a $60 Million financing, and yet the fully diluted market capitalization is less than $70 Million. Within 5 years Rumblings thinks FSNN will sell at a $60 Billion Market Capitalization, about 100 times the current Market Capitalization. !!!

Victory Electronic Cigarettes (ECIG) at $13.48 is the Number Two choice of Rumblings for short and long term capital appreciation. In the United States alone, the E-Cigarette market is projected by industry observers to grow from less than $3 Billion annually today to more than $300 Billion in 5 to 10 years, and the E-Cigarette market worldwide is projected to reach $700 Billion. Victory Electronic Cigarettes, which went public through Goldman, Sachs and other major underwriters less than a year ago, has become the leading E-Cigarette Brand in the U.S., aided by key acquisitions, and ECIG is emerging also as the leading E-Cigarette brand in Western Europe. ECIG has recently achieved annualized revenues of over $100 Million – with sales in major outlets in all 50 states in the U.S. . Market Capitalization is $700 Million, and Rumblings thinks that ECIG stock will climb by 15 times within 2 years – to a market capitalization of over $10 Billion. !!

Neuralstem (CUR) at $3.88 is a biotechnology company that focuses on the development and commercialization of treatments for central nervous system disease based on human neuralstem cells and the use of small molecule compounds. CUR has recently reported that preliminary results in Phase I and Phase 2 trials now underway for the treatment of ALS (Lou Gehrig’s Disease) and also for the treatment of injuries to the spine, have shown results never before achieved. Market Capitalization is only $335 Million currently, and Rumblings thinks CUR will sell at $10.00 within a year, or 3 times the current market price.

Cover-All Technologies (COVR) at $1.43 is a rapidly growing software-based technology company that is on the verge of making significant bottom-line profits as a result of its success in attracting as clients a number of insurance companies, some of which are household names. The Market Capitalization of COVR is only $42 Million and Rumblings thinks that Cover-All Technologies common stock will sell at $7.00 within a year, or 5 times the current market price.

Oramed Pharmaceuticals (ORMD) at $10.56 is a pharmaceutical company engaged in the development of orally ingestible capsules or pills for the treatment of type-1 diabetes and polypeptides. This has the potential to improve compliance and quality of life by reducing injections for diabetes patients. The Market Capitalization of ORMP is only $103 Million, and Rumblings thinks that Oramed will sell at $40.00 within a year, or about 4 times the current price.

ProMetic Life Sciences (PFSCF) at $1.09 is a bio-pharmaceutical company engaged in the research, development, manufacturing and marketing of small molecule therapeutics and protein technologies for various medical needs in the fields of cancer, anemia, fibrosis, neutropenia, and auto-immune related diseases, as well as certain nephropathies. ProMetric Life Sciences has a Market Capitalization of $550 Million, and Rumblings thinks that PFSCF common stock will sell at $4.50 within a year, or 4 times the current price.

Arabian American Development (ARSD) at $10.92 manufactures – in the U.S.- specialty petrochemical products (a very profitable and rapidly growing business) and also has a significant (roughly 50%) interest in the largest gold, copper, zinc,and silver mine in Saudi Arabia, which will be entering its production phase within a year. The Market Capitalization is only $264 Million, and Rumblings thinks that ARSD will sell at $45.00 per share within a year, or 4 times its current market price.

AFLAC (AFL) at $62.66 is the largest seller of specialty health insurance plans in Japan, and AFL has also become a leader in selling supplemental life and health insurance in the United States. The Market Capitalization is $29 Billion and earnings per share are around $6.50 per share, so the common stock of AFLAC is very cheap currently, Rumblings thinks that AFL common stock will sell at $125.00 per share within a year, or 2 times the current price.

BioTime (BTX) at $3.11 is a bio-technology company focusing primarily on research and development in the field of regenerative medicine, which refers to therapies related to embryonic stem cell and induced pluripotent stem cell technology designed to rebuild stem cell and tissue function loss due to degenerative disease or injury. The Market Capitalization is only $276 Million, and Rumblings thinks that BTX common stock will sell at $10.00 per share within a year, more than 3 times the current price.

Hartford Financial Services (HIG) at $34.88 is one of the largest and most successful property and casualty insurance companies in the United States, and HIG is very cheap in relation to its book value, and its potential earning power of $5.00 or better in a good year. The Market Capitalization of Hartford Financial Services is $15.6 Billion, and Rumblings thinks that HIG will sell at $70.00 per share within a year, or 2 times its current market price.

Ray Dirks and his team of Money Managers and Security Analysts suggest that readers/investors place no more than 1% of the money they place in common stocks in any one security. It’s best to diversify. !


The information contained in this Report contains forward-looking statements relating to the developments of the featured company’s products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “believe,”, “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking.

These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company’s most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com.

The information on this Internet Site has been submitted by journalists and analysts or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk



The Best Coverage Money Can Buy

Bloomberg Personal Finance,
April, 2000
Investors sometimes assume that if a stock is covered by one or more brokerage houses, that means they have a fundamentally favorable opinion of the stock's merits. That isn't necessarily so.In the extreme case, brokerage firms (mainly small ones) accept financial inducements to provide coverage. For example, in 1998 J-Bird Music Group (JBRD) retained Security Capital Trading (run by the well-known but controversial analyst Ray Dirks) for advisory services. Security Capital issued a favorable report on J-Bird, which provided Security Capital with 500,000 shares of restricted stock. The existence of those shares was not mentioned in the report. Perhaps you think that such arrangements are a little less than arm's length. But that is only one gross form of the Wall Street coverage game. There are many other forms. Companies that dole out stock offerings to major investment-banking firms have certain (often unspoken) expectations about research coverage. They expect: (1) that the investment banking firm will cover the stock, (2) that it will say favorable things about it, and (3) that it will provide a "booster shot" of favorable coverage not long after the stock offering. These expectations apply to any offering, but especially to the first one, the initial public offering. Brokerage houses that violate these norms often find themselves frozen out of a company's next offering, a fate worse than death these days! --JD

Ray Dirks of Security Capital Trading, Inc. Recommends J-Bird Music Group (OTC Bulletin Board: JBRD) as Strong Internet Growth Stock

WILTON, Conn., July 21 /PRNewswire/ -- J-Bird Music Group, Ltd. todayannounced that it has established an investment banking relationship with thefirm of Security Capital Trading, Inc. Ray Dirks, the well-known securitiesanalyst, is currently recommending the purchase of J-Bird stock, the Wilton,Connecticut-based Internet record label. This comes on the heels of J-Bird'srecent announcement of the signing of rock legend Billy Squier, who has soldmore than 15 million records during his illustrious career.In a 14-page analysis of the company's two-year history and prospects,made public on July 13, 1998 by Security Capital Trading, Inc., J-Bird Recordsis recognized as a company with "huge potential that has not yet beendiscovered by the investment community." The study concludes with therecommendation that "shares of J-Bird are recommended for purchase by veryaggressive, long-term growth oriented investors who are seeking a low-pricedstock that offers a considerable upside potential.""We are extremely impressed with the innovative game plan of the company'sdynamic leader, Jay Barbieri," said Dirks of Security Capital Trading, Inc."The size and growth prospects of the CD segment of the recorded music marketbeing addressed by the company makes use of the Internet to gain exposure fornew artists, as well as formerly successful ones, and takes advantage of thealready well entrenched recording industry marketing and distributionchannels.""Although many Internet-based companies are currently celebratingtremendous success, I believe that continued growth is only inevitable forthose companies like J-Bird that own its content," said J-Bird Music Group'spresident and CEO, Jay Barbieri. "By having this recommendation, from RayDirks, it marks yet another step in our efforts to move toward expanding ourimpact on the recorded music marketplace."In addition to its own record label, web site( and 24-hour Web radio station, J-Bird MusicGroup, founded in 1996, has established a relationship with AT&T's a2b musicservice, whose web site will soon permit customer access to J-Bird's artistmusic. J-Bird has also entered into a national distribution agreement withNavarre Corporation, one of the United States' largest distributors of musicto retail outlets. Their 50,000 accounts include Best Buy, Blockbuster,Borders, Circuit City, HMV and Tower.The full report and analysis can also be accessed at J-Bird Music Group, Ltd.
Web Site:

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content. Copyright © 1996-2002 PR Newswire Association Inc. All Rights Reserved.
A United Business Media company.
Congrats to Ray Dirks for pulling of yet another stock fraud while the SEC continues to look the other way.

Fonu2 Inc. (PC) (FONU)
0.0003 ? -0.0001 (-25.00%)
Volume: 162,869,617 @ 3:59:32 PM ET
Bid Ask Day's Range
0.0002 0.0004 0.0002 - 0.0004

Market Alert: RAY DIRKS RESEARCH: FONU2 (FONU) September 25,2013 by Ray DirksPosted on admin on September 25, 2013 // Leave Your Comment

MARKET ALERT – RAY DIRKS RESEARCH with Ray Dirks and his team of Money Managers and Securities Analysts writes the First Article on the Internet about FONU2 Inc., a rapidly growing, state-of-the-art, U.S.-based business service company developing applications for enterprises to increase the revenues of their businesses in a fashion that has never been done before successfully.

FONU2 develops and provides local mobile applications. FONU2 (FONU) is a public company that trades in the OTC market. FONU2 engages in commerce/service networking. Based in Oakland Park, Florida, FONU was formerly known as Cygnus Internet, Inc., and FONU changed its name to FONU2 Inc. in April, 2012. FONU2 Inc. was founded in 2009.

RAYDIRKS Research believes FONU2 is an incredibly undervalued company, as its stock is under-followed by Wall Street securities analysts and money managers. FONU common stock sells at a price of $0.28 per common share, and its daily average trading volume is 110,000 shares, according to Yahoo Finance. The total number of shares outstanding is 69 million; accordingly, the market capitalization is just $19 million – for a company with an incredible upside potential – perhaps 10 times or more within a year or two.

RAYDIRKS Research believes that FONU2 (FONU) could have the biggest upside potential in the business service area. Last week Ray Dirks met face-to-face with Roger Miguel, who was recently appointed to the Board of Directors and also is serving as Chief Operating Officer. The meeting was in New York City in the Empire State Building, in the offices of Mark Kabbash, who runs EquityGroups, the very successful public relations and investor relations firm. Mr. Kabbash also attended the meeting.

The company just announced, FONU2's Unique Social Commerce Platform which leverages Social Networking and Distinctive Prepaid Reloadable Card. This beta Launch of their distinctive social commerce platform via mobile app FONU2's mobile app is fully integrated with Facebook and available for both Android and iOS, and functions like an order and booking reservation system.

In the company release they describe what we feel is a landmark game changing platform :

“FONU2's distinctively designed platform for social commerce is revolutionary, in terms of its social networking integration, marketing capabilities and seamless transaction process. With precise amalgamation with Facebook, instant transactions backed by Amazon Wallet, and access to list or trade goods or services to a global marketplace, the FONU2 mobile app is a ground-breaking way for users to capitalize on their social networks.

Listing any type of ad with the FONU2 mobile app is simple and quick. First users determine where they want to advertise. Then, users determine if they are posting an ad to sell or trade a service or product. Next, images are uploaded by the user to highlight their service or goods and engage potential customers. After, price options and availability information is selected the ad can be posted. Since FONU2's social commerce platform is Facebook integrated, users can determine if they want to notify friends and family.

The FONU2 platform for social commerce helps sellers or posters get the most out of their ad through a wide-range of marketing and design options and possibilities. Posting any type of ad is also free of charge. Only a small fee is incurred when an item or service sells. Sellers with FONU2 also have peace of mind that their transaction is safe, secure, instantaneous and backed by Amazon Wallet, as each sale is processed via FONU2's prepaid reloadable card.

FONU2's unique reloadable prepaid card facilitates safe trading among global users. The FONU2 social commerce platform allows the 700 million solid daily user base of Facebook to engage in social media, start earning income and market their services or products to a worldwide audience they never would have been able to access.”

One of the key components Ray Dirks feels will be a driving force in this company is the team that they have built:

Just last week, FONU2 announced that “FONU2's Board of Directors are thrilled to welcome Roger Miguel as a member of their council. Roger has already made significant contributions to the success of the FONU2 social commerce platform, acting as Chief Operating Officer, a position he will retain as he is inducted into the Board of Directors.”

“Roger has over 30 years of experience in the field of computer service outsourcing, having worked with the industry leaders in that field. Roger has a solid track record of success helping Fortune 500 companies to improve their operations by optimizing processes, improving quality, and increasing profitability. Through this experience he has developed a keen sense of what a company requires to succeed. This experience has given him a solid foundation to draw upon, as the FONU2 social commerce platform prepares to launch late this year, anticipating rapid growth and the capture of a significant share of the social commerce marketplace.”

Bob Lee, CEO of FONU2, said, “Roger brings a high level of professionalism, knowledge, and experience in the technology field to the Board of FONU2. He offers a wealth of experience from his employment with information and computer technology powerhouses like EDS,CSC and Xerox and he will be a welcome addition to the board as FONU2 continues development of its cutting edge people centric, mobile, social commerce platform.”

And less than two weeks ago, FONU2 announced that it has entered into an agreement with Gamaroff Digital to develop the FONU2 mobile app. “FONU2 selected Gamaroff Digital to develop the mobile face of its social commerce platform because of their extensive experience and expertise developing mobile apps and games integrated with the Facebook platform. The FONU2 mobile application will meld core Facebook technologies integral to the user experience including news feeds, localization and notifications with FONU2's secured global marketplace for social commerce. The FONU2 social commerce platform is comprised of targeted jobs, classified postings, and a prepaid debit card credit payment system for seamless transactions. In the near future, the FONU2 user experience will continue to be developed with the integration of games.

Mr. Mike Gamaroff, CEO of Gamaroff Digital, said, “Having fully comprehensive native mobile accessibility is now essential for all web platforms. We enjoy innovative approaches to mobile commerce and look forward to working closely with FONU2 in developing a product that meets its business objectives whilst demonstrating that the user experience on mobile should be slick, simple, and social.”

“Gen-Y and next-generation consumers with smart mobile devices are on the rapid rise. Reaching these markets with prepaid debt card functionality, and a jobs classified marketing platform tied to mobile, is key to gaining long-term traction within these groups,” said Jeffrey Pollitt, founder of FONU2. “The FONU2-Gamaroff mobile Facebook integration build, strategically and aggressively markets to these market segments.”

Another of FONU2's competitive advantages is its high-level security methodology that vets prepaid debit cardholders unlike any other people centric social commerce platform.

Gamaroff Digital, which has been on Facebook’s Preferred Developer Consultant Program since September, 2009, has been a trusted partner of Facebook in concepting and building socially engaging Facebook and mobile apps for brands such as Virgin, McDonald’s, and SONY PlayStation.

In January, 2010, Gamaroff Digital won two awards out of three at the Facebook Mobile Hack in New York, for best use of Facebook Graph and Best Overall App. In April, 2012, Gamaroff Digital was awarded a Facebook Preferred Marketing Developer badge.

With friends like these – Facebook and Gamaroff Digital, that is - Why would FONU2 worry about competitors in their vast business space – both locally and worldwide ?

Furthermore, FONU2 has also entered into a key strategic relationship with SEO and Investor Relations guru Mark Kabbash .

Mr. Robert Lees, Chief Executive Officer of FONU2, said “FONU2 is thrilled to announce the addition of Mark Kabbash to spearhead our social commerce penetration and investor relations campaign. Given Mark’s outstanding track record helping companies grow, I firmly believe that he will transform FONU2 into a globally recognized brand.”

After acquiring the investor social network, Mark began to unravel the processes behind SEO and social commerce, using both insight and experience to concoct an extremely powerful formula for the organic branding of company web pages for digital sharing.

Mark Stated in the release “What I was able to achieve for the last company I worked with will pale in comparison what I am about to do with the branding of the FONU2 platform,” Mark states. “I fully believe in the mission of this company and the revolutionary nature of their seamless approach to social commerce. Companies like Zynga, Facebook and Google have done well because of their people-centric approach. I fully believe that the companies which are able to understand peer to peer interactions and facilitate them will have a natural advantage, and I see massive potential in FONU2. Under my guidance, I will transform the awareness of this company within the investment community into a buzzword. I intend to utilize all the tricks I have developed during my career to drive this project forward with the most ambitious goals that I can set for myself.”

As Mark Kabbash pointed out to Ray Dirks in a personal interview yesterday, there really are no other companies that are truly comparable to FONU2, which as we’ve said, is a state-of-the-art United States-based pioneering local business company with mobile applications that engages in commerce/service networking in a fashion that will soon bring significant revenue to FONU in a highly profitable manner, thus resulting in a much higher price for the common stock of FONU2 – many times the current price – which values the company at only $19 million.

Ray Dirks believes that FONU2 is a tremendous opportunity for investors to participate in a very hot and up and coming company that brings an amazing management team and products that monetize social networking and social commerce with their new game changing platform.

Ray Dirks and his team of money managers and securities analysts at RAYDIRKS Research suggest that readers of this article and other investors, whether Institutional or Individual, do their due diligence and then consider investing in the common stock of FONU2 (FONU) as soon as possible for its capital appreciation potential of 10 times or more within a year or two.

RAY DIRKS Research suggests that readers/investors place no more than 1% of the money they devote to common stocks in any one security. It’s best to diversify!


The information contained in this Report contains forward-looking statements relating to the developments of the featured company’s products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “believe,”, “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking.

These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company’s most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com.

The information on this Internet Site has been submitted by journalists and analysts or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk

Tags: Commercy,, Equitygroups, Mark Kabbash, platform, prepaid, Ray Dirks, Ray Dirks Research, Social, social mobile

Fonu2 Inc. (PC) (FONU)
0.0003 ? -0.0001 (-25.00%)
Volume: 162,869,617 @ 3:59:32 PM ET
Bid Ask Day's Range
0.0002 0.0004 0.0002 - 0.0004



SEC v. Sky Capital LLC a/k/a Granta Capital LLC, Ross Mandell, Stephen Shea, Adam Harrington Ruckdeschel, Arn Wilson, Michael Passaro and Robert Grabowski, Civil Action No. 09-CV-6129 (SDNY) (PAC)

Litigation Release No. 21120 / July 8, 2009

SEC v. Sky Capital LLC a/k/a Granta Capital LLC, Ross Mandell, Stephen Shea, Adam Harrington Ruckdeschel, Arn Wilson, Michael Passaro and Robert Grabowski, Civil Action No. 09-CV-6129 (SDNY) (PAC)

SEC Charges Broker-Dealer, Founder, Executive and Registered Representatives in Multi-Million Dollar Transatlantic Stock Manipulation Scheme

On July 8, 2009, the Securities and Exchange Commission (Commission) filed a civil injunctive action in the United States District Court for the Southern District of New York charging a New York based broker-dealer, Sky Capital LLC a/k/a Granta Capital LLC (referred to herein as Sky Capital) for using fraudulent boiler room tactics between September 2002 and November 2006 to raise more than $61 million from investors in two related companies — Sky Capital Holdings Ltd. and Sky Capital Enterprises, Inc. (the Sky Entities). The Commission also charged Sky Capital's founder, former President and CEO, Ross Mandell, the firm's former COO, Stephen Shea, and four registered representatives, Adam Harrington Ruckdeschel, Arn Wilson, Michael Passaro, and Robert Grabowski, for orchestrating and participating in the fraudulent scheme designed to fraudulently induce numerous individuals to invest in the Sky Entities.

According to the Commission's complaint, Mandell orchestrated the fraudulent scheme with the assistance of Shea and the other defendants. According to the complaint, Mandell directed Sky Capital brokers to make material misrepresentations, and fail to disclose material information, to induce their Sky Capital customers to purchase stock in the Sky Entities. Mandell also personally made material misrepresentations to his customers. Additionally, the defendants implemented and enforced a "no-net sales" policy, which had the effect of preventing investors from selling their Sky Entities' stocks that were otherwise publicly traded on the Alternative Investment Market of the London Stock Exchange. The no-net sales policy had the effect of artificially inflating the price of the Sky Entities' stocks. Moreover, as a result of the "no-net sales" policy, which the defendants did not disclose to their customers, numerous Sky Capital investors were unable to sell their shares in the Sky Entities before trading in those stocks was suspended thereby rendering the investments worthless.

The SEC's complaint further alleges that the fraudulent scheme was extremely profitable for the defendants. Between 2002 and 2006, Sky Capital raised over $61 million from investors in the U.S. and the U.K. Mandell used the investor funds to subsidize his own lifestyle, including using investor funds for various personal expenses, including first-class travel, five-star hotel stays, expensive meals, adult entertainment, and child-care expenses. Mandell also used investor funds to richly compensate the other individual defendants by paying them hefty undisclosed commissions and giving them other perks.

The SEC's complaint charges each of the defendants with violations of Section 17(a) of the Securities Act of 1933, and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. The complaint also, in the alternative, charges Shea with aiding and abetting the other defendants' violations of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder. Additionally, the SEC's complaint charges Sky Capital with violating Section 15(c) of the Exchange Act, and Mandell with aiding and abetting Sky Capital's violation of Section 15(c) of the Exchange Act. The complaint seeks a final judgment permanently enjoining the defendants from future violations of the above provisions of the federal securities laws, ordering them to disgorge their ill-gotten gains plus prejudgment interest, and ordering them to pay civil penalties. The complaint also seeks to permanently prohibit Mandell from acting as an officer or director of any registered public company.

SEC Complaint

Home | Previous Page Modified: 07/08/2009


Ray Dirks latest SCAM promoted by Gene Marcial formerly of Businessweek who promoted Dirks in his columns back then also.


About is a one stop resource for the hottest stock news and stock picks from financial gurus and analysts. provides access to cutting edge investment newsletters and small cap reports, as well as real-time updates from the latest up-and-coming small and microcap companies through its sister site, Be informed with! Featured on is Wall Street legend Ray Dirks’, market commentary column.

Ray Dirks

Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high -net worth investors both in the U.S. and internationally.

In 1973 Ray uncovered the biggest Ponzi scheme of the 20th century, the Equity Funding fraud. Equity Funding Corporation, listed on the New York Stock Exchange, had been widely touted as the fastest -growing large insurance company in the country, but Ray’s research, which he conveyed to The Wall Street Journal and Barron’s, exposed the fraud in less than 30 days. Over 20 officers and accountants and lawyers went to jail, However, as the man who blew the whistle on this Ponzi scheme, Ray himself was charged by the SEC with civil fraud and was forced to battle the Securities and Exchange Commission all the way to The Supreme Court where Ray won the landmark 1983 decision on Inside Information violations, known widely as The Dirks Decision.

Over the years Ray has expanded his stock market research to include Healthcare Stocks and Special Situations, including Heavily Shorted Stocks, an area where Ray became widely known as the founder and principal researcher of The ShortBusters Club.

Ray has written two books,” The Great Wall Street Scandal” and “Heads You Win, Tails You Win”, published by McGraw-Hill and Bantam Books respectively. He continues to provide research to institutions and individuals, and he manages money for some individual investors.

Gene Marcial

Gene G. Marcial was Business Week’s “Inside Wall Street” columnist for 28 years until Dec. 2, 2009, when Bloomberg took over the magazine. He is also a former columnist at the Wall Street Journal, where he wrote the “Heard on the Street” column and the “Abreast of the Market” column for more than seven and a half years.

Marcial now writes the “Street Beat” column for Forbes and continues to be one of the most influential stock columnists, closely watched by investors and corporate executives alike. When he was writing the column for Business Week, a favorable mention often resulted in a jump in the stock price on the first trading day the magazine became available to the public.

“It is well understood that trading in the stock market is full of risks. But if you are ready to take the plunge, I guarantee that there will be a time when being familiar with Gene Marcial’s 7 Commandments of Stock Investing will be extremely important. Over the years, I have followed many of the same commandments.” Those were the words of a legendary investor Carl Icahn, Chairman of Icahn Associates, in his endorsement of Marcial’s book, “Gene Marcial’s 7 Commandments of Stock Investing,” published in 2008 by FT (Financial Times) Press.

Marcial’s first book was “Secrets of the Street, the Dark Side of Making Money,” published in 1995 by McGraw-Hill Publishing. It was one of the early books that told all about the rampant insider trading activity on Wall Street, where Marcial argues the financial system, the very heart of the capitalistic system, breeds greed, corruption, and irresistible temptation. In its review of the book, Newsweek said: “A frightening look at how inside trading remains widespread years after Ivan Boesky’s parole.” That was in 1995. So much more insider trading scandals have captured headlines since then.

Marcial received an undergraduate degree in Journalism from the Santo Tomas University in Manila before studying law at the New York Law School and receiving a graduate degree in Political Science from New York University.

Additional reports contributed by:
Rob Goldman

Rob Goldman has 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray’s Technology research team covering Israeli Technology and Communications Software. Prior to joining Piper, Rob led Josephthal & Co.’s Washington-based Emerging Growth Research Group as well as the Firm’s Israeli research team. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Additional Reports by:
Timothy Sykes

Timothy Sykes is the #1 ranked trader out of 60,000+ on Covestor and the CEO and Co-Founder of, a community of over 15,000 traders who shares their trades openly and, a financial product review website with nearly 20,000 original reviews on brokers, newsletters, websites and everything else financial. Follow him on Twitter @timothysykes and for more info go to: to and

Additional reports contributed by:

Brad Greenspan

Brad Greenspan is a successful Internet entrepreneur and investor who has facilitated numerous US & Asian investment and business transactions. He is the Founder of social networking giant MySpace and he is regarded as one of the pioneers of the social networking sector. As the Former CEO and Chairman of eUniverse / Myspace, Brad was primarily responsible for increasing the value of the organization from zero (when it was launched in 1999) to $580 million when it was acquired by Rupert Murdoch’s News Corp. in 2005. Brad’s portfolio of start up and early stage companies has covered a broad range of sectors including: Big Fish Games (gaming), Borba Corporation (neutracuticals), Fluid Music (music), Draths (clean technology). He is also the Founder and Chairman of Broadweb Asia a leading Asian focused online entertainment Company. Brad is also the Founder CEO and Chairman of Live Universe a social networking aggregator
Brad received a BA from UCLA

Additional Reports contributed by:
Len Bogner

Leonard Bogner is President of Bogner Business Associates LLC, a diversified management consulting/financial and public relations firm with unique specialization in the chemicals and allied products industries. Prior for forming his consulting organization in 1994, Mr. Bogner spent more than 20 years on Wall Street as a Senior equities research analyst (mainly at Prudential Securities), where he followed major diversified chemical and micro-cap companies. He was a perennial Institutional Investor All-Star selection and named to the Wall Street Journal “Best Analysts” list in Chemicals in 1989, 1992 and 1993. Prior to joining Wall Street, Mr. Bogner worked as a Senior Editor on McGraw-Hill’s Chemical Week Magazine, where he received the prestigious Jesse H. Neal Award from the American Business Press for articles relating to “Nader vs. DuPont.” He has served as a Director of a public company, worked with a leading private equity group’s Executive Network, and been a guest speaker at many chemical industry company and association forums.

Additional articles contributed by:
Robert Liscouski

Robert Liscouski was appointed by President George W. Bush as the first Assistant Secretary for Infrastructure Protection when the U.S. Department of Homeland Security was founded in 2003 and he served in that position until 2005.

As a former senior executive at the U.S. Department of Homeland Security, Mr. Liscouski is a recognized expert in Homeland Security including Risk Management and Corporate Security; Infrastructure Protection; Protection of U.S. Interests abroad; and National Security. In Infrastructure Protection, his expertise includes Transportation Security, Air Cargo Security, Chemical Security, Soft Targets, and Improvised Explosive Devices.

During his tenure at the U.S. Department of Homeland Security, Mr. Liscouski was responsible for the design, development, implementation and oversight of numerous programs including The Office of Infrastructure Protection Directorate which had a budget of over $500 million in one year.

Prior to joining the U.S. Department of Homeland Security, he was Director of Information Assurance at the Coca-Cola Company and Vice President of the Law Enforcement Division of Orion Scientific Systems.

He is currently a visiting fellow at the Center for Strategic and International Studies, as Washington D.C. based think tank and was a board member of the Intelligence Science Board supporting the Director of the Central Intelligence Agency and the Director of National Intelligence for 12 years. He also serves on the Board of Directors of Implant Sciences, a high technology supplier of systems and sensors for homeland security markets.

Mr. Liscouski is also currently a partner in Secure Strategy Group, LLC, a New York and Washington DC based investment bank dedicated to backing and building market leaders in the security and defense technology sectors. He is also founder and Managing Director of Edge360 an enterprise risk management and technology solutions firm and a founder of Steel City Re, a firm specializing in reputation risk and intangible asset risk management.

He holds an MPA from the Kennedy School of Government, Harvard University and a B.S. in Criminal Justice from the John Jay College of Criminal Justice.

Additional articles Contributed by:

Scott L. Greiper

Mr. Greiper has had a distinguished 15-year career in the security and defense industries as both an equity research analyst and investment banker. He is the founder and President of the Secure Strategy Group, a banking and advisory firm that backs and builds growth companies in the security and defense technology markets. Before this he was a Managing Director at Legend Merchant and Head of the firm’s Convergent Security Group, which provided capital, strategic advisory and M&A services to security and defense technology companies. Previously, Mr. Greiper was a Principal and Senior Equity Analyst at C. E. Unterberg, Towbin, where he published research on public companies in the Global Security industry. He was ranked as one of the top analysts in the sector for the performance of his research and trading recommendations. Mr. Greiper has raised over $300 million in capital for public and private security firms and has completed a range of M&A assignments. He attended the Executive MBA program at Columbia University and holds a B. A. in Economics from The University of Chicago.

Additional articles contributed by:
Dr. William Prather

Dr. Prather has been with Pluristem Therapeutics since 2006. He received his BS in Pharmacy and medical degree from the University of Missouri. Besides holding senior healthcare research positions for a variety of investment banks, Dr. Prather co-founded Panacos, Inc., a public pharmaceutical company

Additional articles contributed by:
Sam Seiden:

As the VP of Education at Online Trading Academy, Sam brings over 15 years of experience in equities, forex, options and futures trading which began when he was on the floor of the Chicago Mercantile Exchange where he facilitated institutional orderflow. He has traded equities, futures, interest rate markets, forex, options, and commodities for his personal interests for years and has educated thousands of traders and investors through seminars and daily advisory services both domestically and internationally. Sam has been involved in the markets since 1991 both on and off the floor of the Chicago Mercantile Exchange. He has served as the Director of Technical Research for two trading firms and regularly contributes articles to industry publications. Sam is known for his trading, technical research, and educational guidance.

In February 2011, Sam won the Forex Best Awards in the categories of Best Educator, Best Educational Content, and Best Webinar from, the leading independent portal dedicated to providing complete and timely information about the Foreign Exchange (Forex) market.

Additional articles and reports contributed by

R. Jerry Falkner, CFA, President, RJ Falkner & Company, Inc.

RJ Falkner & company, Inc. is an independent investment research and financial communications firm that is focused on small- and micro-cap companies with the potential to significantly outperform the overall stock market over at 12-18 month time frame.

R. Jerry Falkner began his analytical career as a member of the institutional research department with Houston-based Underwood, Neuhaus & Company, Inc. in 1969, shortly after graduating summa cum laude from the University of Houston, where he majored in Economics/Finance. Mr. Falkner’s 14-year tenure with that firm, where he served as a “special situations” analyst and Director of Retail Research, was followed by three years with the research department of Johnson, Lane, Space, Smith & Company (predecessor to Interstate Johnson Lane and Wachovia/IJL) in Atlanta, Georgia.

In February 1986, Mr. Falkner returned to Texas, where he joined Lovett Mitchell Webb & Garrison (LMW&G) as Senior Vice President and Director of Special Situations Research (LMW&G was later acquired by Kemper Financial Services). In 1988, he moved to Florida to establish a research department at Gulfstream Financial Associates (a subsidiary of Kemper Financial). In June 1990, Mr. Falkner and two other executives left Gulfstream and co-founded Southeast Research Partners, Inc., an institutional sales/research boutique headquartered in Boca Raton, Florida.

A Chartered Financial Analyst since 1976, Mr. Falkner is a member of the Austin Financial Analyst Society, the Association for Investment Management and Research (AIMR), the International Chartered Financial Analysts Association, the National Association of Business Economists, and the National Investor Relations Institute. He has been quoted in the Wall Street Journal, the Dow-Jones News Service, Reuters, Bloomberg Business News and other financial media services and trade publications.

Mr. Falkner founded RJ Falkner & Company, Inc. in 1991. He lives and works in Austin, Texas; Crested Butte, Colorado; and Sedona, Arizona.

Additional articles contributed by:
Sharon di Stefano

Sharon di Stefano has spent 20 years as a healthcare analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies.

Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense. Past speaking and consulting engagements include the creation of a pharmaceutical pipeline database for Blue Cross of California; analysis of diagnostic and treatment trends in Hepatitis B for Synergy Pharmaceuticals; business valuation for Wasserstien Perella; bankruptcy workout for FleetBoston Capital Corporation; valuation of a new 250-company ‘fund of funds’ for AON Corporation.

Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.

Additional articles contributed by:
Dr. Karuna Sabnani

Dr. Karuna Sabnani is a Beauty and Natural Medicine Expert. For over 10 years, patients have come to Dr. Sabnani to learn how to get a lean body, restful sleep, restored energy, clear skin, strong digestion and stress reduction. Patients often feel a sense of ease, balance and health within their full lifestyles and demanding careers after following Dr. Sabnani’s suggestions.

Dr. Karuna Sabnani is a graduate of Southwest College of Naturopathic Medicine, an accredited four-year naturopathic medical college. She received her Bachelor of Arts degree in Psychology and English Literature from Mount Holyoke College in Massachusetts. Dr. Sabnani is licensed as a Naturopathic Doctor in the state of California, and is a member of the California Association of Naturopathic Doctors. Dr. Sabnani has practiced in Arizona, California and New York City since 2001. She currently lives in New York City and works with patients both nationally and internationally.

Using Ayurvedic principles and Natural Wisdom, Dr. Sabnani designs a personalized health regime or cleanse, often referred to as a “Health & Beauty Makeover’, specific for the patient’s lifestyle. She uses a creative and inspirational approach. Her goal is for her patients to glow in radiant health.

In addition to her general practice, Dr. Sabnani blogs for the Huffington Post and is the health and beauty advisor to IMAN Cosmetics. She is also a part of Illumé, a unique image consulting and wellness service that re-interprets the concept of personal styling.

© 2010 CP Reports · Disclaimer · Subscribe: Posts Comments · Designed by Theme Junkie · Powered by WordPress

Ross Mandell Arrives at Courthouse to Appeal Conviction – PHOTO by Rick Maiman


Stock Promoter Dirks Out of a Job

BY Matthew Goldstein 04/16/04 - 10:11 AM EDT

Ray Dirks, one of Wall Street's better-known boosters of small-cap stocks, resigned this week from his managing director's job at Sky Capital, a New York investment bank.

A source familiar with the situation says Sky Capital permitted Dirks to resign on Wednesday, but the firm probably would have demanded his resignation if he didn't leave of his own accord. Dirks' departure comes four months after the NASD filed an enforcement action alleging that the 69-year-old analyst and broker pumped up a handful of penny stocks while working at Dirks & Co., a now-defunct brokerage owned by his wife.

Regulators contend the couple failed to tell customers that they were making a market in stocks they were simultaneously praising in their in-house research. A hearing date for the NASD proceeding hasn't been set.

The investment bank confirmed Dirks no longer works at the firm. Sky Capital President Michael Recca declined to comment on the reasons behind Dirks' departure.

Dirks could not be reached for comment at his home. His lawyer, Joseph Tandet, declined to discuss the reasons behind Dirks' resignation. Before he became an advocate -- some would say a tout -- for small cap-stocks, Dirks was best known for battling the Securities and Exchange Commission all the way to the U.S. Supreme Court on an insider trading charge -- and winning. In that battle, the SEC charged Dirks, then an insurance industry analyst, with insider trading for quietly telling some of his big brokerage clients about a massive accounting fraud at a company called Equity Funding. The Supreme Court, in a landmark 1983 decision, sided with Dirks and ruled he was only doing his job as an analyst. But since then, Dirks has been often associated with the stocks of dubious merits. Most recently, he was the contact person for Sky Capital on the initial public offering for Vaso Active Pharmaceuticals, a tiny over-the-counter drug manufacturer that was one of the hottest stocks of the year before the SEC suspended trading in its share earlier this month. Sky Capital, a three-year-old investment firm with offices in New York and London, was all set to bring the Vaso Active deal to market last fall but at the last minute the NASD objected. Sources say the securities industry's self-regulatory organization told Vaso Active to find a new underwriter because Sky Capital had no prior experience working on an IPO. Kashner Davidson, a small Florida brokerage, subsequently replaced Sky Capital on the IPO. On April 1, the SEC suspended trading in shares of Vaso Active after finding it may have made misleading statements about some of its products, including an Athlete's Foot treatment called Termin8. Matt Meister, Kashner's president, declined to comment on the trading suspension.


Sky Capital Holdings Ltd Names Ray Dirks as Managing Director Of Institutional Sales and Adam Harrington

Managing Director Of Retail Sales at Sky Capital LLC

    NEW YORK, Aug. 19 /PRNewswire/ -- Sky Capital Holdings Ltd today     

announced the appointment of Ray Dirks as Managing Director of Institutional Sales and Adam Harrington as Managing Director of Retail Sales of Sky Capital LLC, the firm's U.S.-based brokerage entity. Mr. Dirks, a legendary Wall Street securities analyst, will be responsible for building Sky Capital's institutional sales efforts in the United States. Formerly of Dirks & Co., a well-known research and brokerage firm, Mr. Dirks grew to prominence when he uncovered the Equity Funding fraud in 1973, which led to a landmark legal victory before the U.S. Supreme Court. "Ray Dirks provides an enormous amount of experience and acumen in the financial services arena. As Sky Capital builds its operations he will be an integral part of our growth," said Michael Recca, president of Sky Capital LLC. Mr. Dirks is bringing with him a core group of skilled professionals to accelerate the firm's institutional reach and will be adding capable, experienced and senior level executives to his staff. Adam Harrington has been named to the position of Managing Director- Retail Sales. He will be responsible for spearheading the growth of Sky Capital's retail sales operation in New York. Following approval by the Financial Services Authority (FSA) in Great Britain, Mr. Harrington will also take on responsibility for the Company's brokerage initiative in the United Kingdom, where Sky Capital Holdings Ltd recently floated a successful initial public offering on the Alternative Investment Market of the London Stock Exchange (SKY.L). He will also be developing sales strategies for the firm in other European markets. Mr. Harrington has also brought with him additional experienced investment sales professionals to facilitate the launch of the company's retail sales activities in the United States. Mr. Harrington has considerable experience in the securities industry having held senior positions with a variety of companies. From January 2000 to August 2002 he was Senior Vice-President of the Thornwater Company, an investment bank. During 1999 Adam was President and CEO of Internet retailers,, Inc. and, Inc. From 1995-1999 he was a registered representative and an equity owner of New York-based broker/dealer, Roan Capital Partners. He also has experience in working in the Emerging Markets Division of the Securities and Exchange Commission (SEC) and has a degree in International Business from Hofstra University of New York.

Ross Mandell, CEO Sky Capital Holdings Ltd, commented:

"I am delighted to announce the appointment of Adam Harrington to Sky
Capital's senior management team. He is an immensely capable executive
with experience at the highest management levels. I am confident that
he is the right person to execute our strategy of expanding Sky's sales
operations within both the U.S. and European markets. Following our
recent successful listing on the Alternative Investment Market (AIM)
of the London Stock Exchange I believe that a new chapter is opening
in the corporate history of Sky Capital. People of Adam's caliber and
experience are ideally suited to help us expand on our existing successes."
About Sky Capital Holdings
Sky Capital Holdings Ltd. is a recently incorporated company established
to provide financial and investment advisory services to corporate
clients and private individuals both in the United States and the United
Kingdom, and eventually the rest of Europe. The Company has two wholly
owned subsidiaries: Sky Capital LLC in the United States, and Sky Capital
Ltd. in the UK. Based in two of the most important financial centres in
the world -- New York and London -- Sky Capital Holdings addresses the

need for financial advice and working capital customized for small and
medium sized companies with market capitalisations of $10 million to $100

SOURCE Sky Capital Holdings Ltd
For FIVE GRAND InvestorsHub will spam your fraudulent stock promotion.

Ray Dirks


World Renowned Research Firm recommends Lithium Exploration Group

"We continue to think LEXG will appreciate to $1.00 or Higher!"

The recent market sell-off provides a special buying opportunity, Ray Dirks and his team of money managers and security analysts is now recommending Lithium Exploration Group at the extremely low price of $0.14 per share.

"Ray Dirks thinks that Lithium Exploration Group will go up to between $8.00 and $10.00 per share over the Long Term"

The experienced management team of LEXG has announced a dramatic new development - an acquisition in the waste disposal field - " a multi million dollar opportunity, which, on its own, could generate immediate profitability thus freeing cash flow to fund other aspects of the company's strategy."

Blue Tap, Inc., is the company's first Class 1A disposal well is located outside of Edmonton. They have recently executed an LOI to Acquire additional waste disposal facilities in Alberta. "LEXG's acquisitions in the waste disposal business in Canada will generate immediate profitability. This along with the go-forward strategy to become an institutional acquirer of regional facilities opens the flood gates to a Multi-Billion Dollar Industry"

They also have executed an LOI to acquire Canadian oil and gas producer, Golden Spike Energy. LEXG will own the oil and gas producer and operator as a wholly owned subsidiary. This effort to acquire cash flow will allow the technology R&D and lithium exploration efforts of the company the runway required to provide ultimate value to shareholders.

They already have Lithium assets in place and over 650,000 acres of metallic industrial mineral rights in Valleyview Canada (with 43-101 and mineral processing research for production)

The technology is the kicker because it makes all of these subsidiaries extremely more profitable and on top of that they have exclusivity not only for mining but also the ability to distribute the technology to other industries and to create another a Multi-Million Dollar Revenue Stream!!!

Ultrasonic Cavitation Technology :

Through its relationship with the technology owner, GD Glottech International, the company has certain rights to an ultrasonic cavitation technology used for hydrocarbon upgrading and waste water treatment. It has exclusive distribution rights to the mining industry throughout Canada, and non-exclusive distribution rights to other industrial and municipal applications for the technology. The upside potential for this technology is enormous, particularly in Western Canada where the company has been building relationships steadily since 2010.

All of the acquisitions all play together because Lithium is produced from waste water created by oil and gas production and there are tens of thousands of wells in Canada that need to dispose of the waste water. Having a vertically integrated strategy to make money on all aspects of oil/gas, lithium and waste disposal makes sense!!!

Latest News On Lithium Exploration Group (LEXG:OB)

Investors Hub Disclaimer
Investors Hub has been paid a total of $5,000 (Five Thousand Dollars) by Ultimate Effects for the distribution of this email. Although we have sent you this email, Investors Hub does not endorse this product or company nor is it responsible for the content of this ad. We have not independently reviewed the information, claims and testimonials provided within the advertisement and make no guarantee or warranty regarding its content. The opinions and recommendations expressed in this email advertisement are not those of Investors Hub.

Please note if you would prefer to not receive update emails from Investors Hub, click here to manage your email subscriptions.

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
544Ray Dirks may have been paid fees by some of the companies featured on this siStockDung-8/16/2017
543Crooked Ray Dirks is back. Seems to have left off the massive frauds he was invoStockDung-1/27/2017
542SEC Obtains Final Judgments in the Sky Capital Boiler Room Case U.S. SECURITIESStockDung-4/14/2016
541Wednesday, January 20, 2016Pluristem to Commence Go-To-Market Pivotal Trial in 2StockDung-1/22/2016
540More Ray Dirks Ziasun cohorts headed to the slammer. Ray Dirks former associatesStockDung-11/5/2015
539‘American Greed’ Show to Portray Local Family’s Losses in ScamThe Rev. David AsStockDung-10/29/2015
538Wall St. watchdog expels N.Y. brokerage for kickback scheme Wed Oct 7, 2015 12:StockDung-10/7/2015
537Now trading at .00045 cents->Ray Dirks Research Upgrades Lithium Exploration StockDung-7/31/2015
53650. On June 24, 1996, H. J. Meyers & Co. Inc. ("Meyers") and theirStockDung-5/16/2015
534Sky Capital's Ross Mandell Loses Bid For Supreme Court Appeal 2/23/2015 @ StockDung-2/23/2015
533Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha By Adam Feuerstein | StockDung-12/16/2014
532Ex-Sky Capital Executive Gets 30 Months Prison for Scam By Erik Larson Nov 13,StockDung-11/13/2014
531 D. Strebinger and Chapman Coordinate the Stock Promotion that is Paid for bStockDung-11/7/2014
530BusinessWeek’s Gene Marcial says his sources have no conflicts—but they often doStockDung-10/4/2014
529 RAY DIRKS Research Recommends: Genesis Biopharma (GNBP) March 25, 2011Posted oStockDung-10/4/2014
528GBG paid Ray Dirks twenty-five thousand dollars from the total GNBP budget for rStockDung-10/4/2014
527The Sky Capital Saga Nearing Its End As Mandell Enters Prison 9/12/2014 @ 8:56StockDung-9/12/2014
526Dodd-Frank, 'Morrison' and Global Securities Transactions Chaim A. LevStockDung-8/19/2014
525'Bad boy' broker Mandell's boiler room conviction is upheld By JonStockDung-5/16/2014
524 Wall Street’s “bad boy” imprisoned for 12 years A former manager of Sky CapitaStockDung-5/14/2014
523Corporate Profile, LLC has been paid a fee by some of the companies featured on StockDung-5/2/2014
521Funny how Dirks has NO disclosure as to being paid as a tout. =================StockDung-1/29/2014
520More Ray Dirks cons->Title: GREAT WHITE MARINE & RECREATION, INC. ANNOUNCStockDung-1/27/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):